PubRank

M S Ernstoff

Author PubWeight™ 76.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996 9.68
2 Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999 5.95
3 High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001 4.84
4 High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000 4.60
5 Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000 2.37
6 Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol 2012 2.20
7 Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 1996 2.06
8 Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992 1.58
9 High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst 1990 1.51
10 A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 1999 1.46
11 In vivo description of dendritic cells in human renal cell carcinoma. J Urol 1999 1.23
12 Interferons in the treatment of human cancer. J Clin Oncol 1984 1.22
13 Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy 2006 1.11
14 Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997 1.08
15 Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985 0.98
16 Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods 2001 0.94
17 A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985 0.94
18 Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999 0.94
19 A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 2000 0.94
20 An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol 1992 0.93
21 Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol 1993 0.93
22 Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. J Urol 1991 0.92
23 Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res 1998 0.89
24 Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995 0.88
25 Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol 1987 0.87
26 Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder. Cancer 1990 0.86
27 Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am J Pathol 2001 0.86
28 Sonographic characteristics of epidermoid cyst of testicle. Urology 1990 0.85
29 Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital. Arch Dermatol 1987 0.85
30 Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. Bone Marrow Transplant 2007 0.83
31 Role of interferons in the therapy of melanoma. J Invest Dermatol 1990 0.83
32 Dysplastic nevi in association with multiple primary melanoma. Cancer Res 1988 0.83
33 T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res 1997 0.82
34 Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer 1991 0.82
35 DNA analysis of multiple synchronous renal cell carcinomas. Cancer 1990 0.81
36 A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology 1991 0.81
37 Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute. Melanoma Res 1993 0.81
38 Subcellular localization of metallothionein IIA in human bladder tumor cells using a novel epitope-specific antiserum. Toxicol Appl Pharmacol 1994 0.80
39 Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods 2001 0.80
40 Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 2001 0.79
41 Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med 1984 0.79
42 Comparison of nonfamilial and familial melanoma. Dermatology 1992 0.78
43 Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol 1995 0.78
44 In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol 1990 0.78
45 Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol 1998 0.78
46 Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod 1983 0.78
47 Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. J Immunol Methods 2001 0.78
48 Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. J Chemother 2003 0.78
49 Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol 1989 0.78
50 Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice. J Nucl Med 1987 0.77
51 Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology 1992 0.77
52 Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells. J Immunother (1991) 1991 0.77
53 Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994 0.77
54 Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother 1995 0.77
55 Toxicity comparison of neoadjuvant versus adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in radical cystectomy patients. J Surg Oncol 1990 0.77
56 Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. J Am Acad Dermatol 1992 0.77
57 Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials. J Biol Response Mod 1983 0.76
58 Candida epiglottitis in an adult with acute nonlymphocytic leukemia. Am J Med 1987 0.76
59 Diagnosis of the dysplastic nevus in different populations. J Am Acad Dermatol 1986 0.76
60 Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor. J Immunother (1991) 1991 0.76
61 Dysplastic nevi in relation to superficial spreading melanoma. Cancer Epidemiol Biomarkers Prev 1993 0.76
62 Immunophenotypic markers in renal cell carcinoma. Mod Pathol 1990 0.75
63 The pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1994 0.75
64 Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients. J Immunother 1997 0.75
65 Toxicity of intravesical recombinant human tumor necrosis factor in cynomolgus monkeys. J Biol Response Mod 1990 0.75
66 Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor. J Natl Cancer Inst 1992 0.75
67 A technique for catheterization and cystoscopic evaluation of cynomolgus monkey urinary bladders. Lab Anim Sci 1988 0.75
68 Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study. Am J Clin Oncol 1995 0.75
69 Quantitative DNA analysis of small renal cortical neoplasms. Hum Pathol 1991 0.75
70 Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer. Methods Mol Med 2001 0.75
71 Interferon alpha in combination with other biologics: the scientific rationale. Br J Haematol 1991 0.75
72 Carcinoma of unknown primary: a 20 year retrospective analysis. Conn Med 1985 0.75
73 A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma. Invest New Drugs 1995 0.75
74 Effect of intravenous recombinant alpha-2 interferon on monocyte Fc-dependent phagocytosis in patients with malignant melanoma. J Interferon Res 1984 0.75
75 Immunohistochemical phenotyping of malignant melanoma. A procedure whose time has come in pathology practice. Pathol Annu 1990 0.75
76 Coumarin plus cimetidine: yet another angle for therapy of renal cell carcinoma. J Clin Oncol 1987 0.75
77 Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment. Cancer Res 1984 0.75
78 Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma. J Invest Dermatol 1985 0.75
79 5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. J Urol 1996 0.75
80 Usefulness of frequent skin examination for the early detection of second primary cutaneous melanoma. Cancer Detect Prev 1989 0.75
81 Therapeutic applications of cytokines for immunostimulation and immunosuppression: an update. Prog Drug Res 1996 0.75
82 Analysis of granulocyte-macrophage progenitor cells in patients treated with recombinant interferon alpha-2. Am J Med 1985 0.75
83 Intrapatient and interpatient comparison of tumor size and monoclonal antibody uptake in melanoma. Clin Nucl Med 1988 0.75
84 A clinical update: the role of interferon in the biotherapy of solid tumors. Oncol Nurs Forum 1989 0.75
85 Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst 1990 0.75